Relafen 750, structurally known as naproxen, represents a noteworthy case study from a pharmacological pharmacy standpoint. The drug exhibits its therapeutic effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin synthesis . The targeted inhibition of COX-2, compared to older